Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis.
Wu Z, Huang S, Li T, Li N, Han D, Zhang B, Xu ZZ, Zhang S, Pang J, Wang S, Zhang G, Zhao J, Wang J. · 2021
Read Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis. by Wu Z, Huang S, Li T, Li N, Han D, Zhang B, Xu ZZ, Zhang S, Pang J, Wang S, Zhang G, Zhao J, Wang J. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8424887.txt.
Introduction
Wu and co-authors test how green tea compounds ease gut inflammation through gut microbes. The tea compound EGCG helps in inflammatory bowel disease models. Whether gut bacteria carry that benefit was not known.
Oral EGCG eased colitis in mice and kept the gut barrier sound, while rectal dosing did not. The treatment raised Akkermansia bacteria and butyrate output. Giving EGCG before disease onset worked much the same way. It boosted bacteria that make short-chain fatty acids. Transplants of gut microbes from treated mice eased colitis in new mice. Sterile filtrate tests backed the microbe link. The work ties tea polyphenols to gut health through bacteria.
Catalog record
| CREATOR | Wu Z, Huang S, Li T, Li N, Han D, Zhang B, Xu ZZ, Zhang S, Pang J, Wang S, Zhang G, Zhao J, Wang J. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis By Zhenhua Wu, Shimeng Huang, Tiantian Li, Na Li, Dandan Han, Bing Zhang, Zhenjiang Zech Xu, Shiyi Zhang, Jiaman Pang, Shilan Wang, Guolong Zhang, Jiangchao Zhao Published in: Microbiome DOI: 10.1186/s40168-021-01115-9 ABSTRACT Abstract Background Alteration of the gut microbiota may contribute to the development of inflammatory bowel disease (IBD). Epigallocatechin-3-gallate (EGCG), a major bioactive constituent of green tea, is known to be beneficial in IBD alleviation. However, it is unclear whether the gut microbiota exerts an effect when EGCG attenuates IBD. Results We first explored the effect of oral or rectal EGCG delivery on the DSS-induced murine colitis. Our results revealed that anti-inflammatory effect and colonic barrier integrity were enhanced by oral, but not rectal, EGCG. We observed a distinct EGCG-mediated alteration in the gut microbiome by increasing Akkermansia abundance and butyrate production. Next, we demonstrated that the EGCG pre-supplementation induced similar beneficial outcomes to oral EGCG administration. Prophylactic EGCG attenuated colitis and significantly enriched short-chain fatty acids (SCFAs)-producing bacteria such as Akkermansia and SCFAs production in DSS-induced mice. To validate these discoveries, we performed fecal microbiota transplantation (FMT) and sterile fecal filtrate (SFF) to inoculate DSS-treated mice. Microbiota from EGCG-dosed mice alleviated the colitis over microbiota from control mice and SFF shown by superiorly anti-inflammatory effect and colonic barrier integrity, and also enriched bacteria such as Akkermansia and SCFAs. Collectively, the attenuation of colitis by oral EGCG suggests an intimate involvement of SCFAs-producing bacteria Akkermansia, and SCFAs, which was further demonstrated by prophylaxis and FMT. Conclusions This study provides the first data indicating that oral EGCG ameliorated the colonic inflammation in a gut microbiota-dependent manner. Our findings provide novel insights into EGCG-mediated remission of IBD and EGCG as a potential modulator for gut microbiota to prevent and treat IBD. [Figure: Video Abstract] Supplementary Information The online version contains supplementary material available at 10.1186/s40168-021-01115-9. Keywords: Green tea polyphenol, Colitis, Gut microbiota, Fecal microbiota transplantation, Sterile fecal filtrate INTRODUCTION Inflammatory bowel diseases (IBD), clinically consisting of ulcerative colitis and Crohn’s disease, are chronic inflammatory diseases of the gastrointestinal tract [1]. They are becoming more prevalent worldwide in recent years [2]. The fact that IBD is associated with dysregulation of the gut microbiota [3, 4], and a significant loss in multiple short-chain fatty acids (SCFAs)-producing bacteria was represented in IBD patients [5]. Also, previous evidences have supported SCFAs as key molecules between the microbes and host metabolism, and SCFAs-producing bacteria attract attention [6, 7]. Recently, manipulation of the gut microbiota and its metabolites has potential for IBD therapy, such as fecal microbiota transplantation (FMT) [8, 9]. Moreover, numerous epidemiological evidences support that daily diets impact the risk in chronic diseases such as IBD [10, 11]; however, it is still unclear whether it is mediated by changes in microbiota composition. Daily consumption of green tea, and diets rich in natural polyphenols have been linked to a reduced risk of IBD [10, 12, 13]. Green tea polyphenol Epigallocatechin-3-gallate (EGCG), a major bioactive polyphenol in green tea, possesses anti-inflammatory and anti-oxidative properties [14, 15], with known therapeutic benefits in a murine model of colitis [16, 17]. It has been reported that the gut microbiota also contributes to the metabolism of tea polyphenols to facilitate the clearance of toxic reactive metabolites in cells [18, 19]. Also, previous studies have suggested that the cross-talk between gut microbiota and host oxidative and inflammatory response is pivotal to maintain intestinal health and barrier function [20–22]. But whether the gut microbiota plays a role in EGCG-mediated alleviation of IBD is still unclear. Considering the potential interaction of gut microbiota and EGCG, we hypothesize that attenuation of colitis by EGCG is mediated mainly through modulation of the gut microbiota, which subsequently leads to alleviation of inflammation and oxidative stress in the host [11, 23]. In this study, the alleviated effect of oral or rectal administration of EGCG was first tested in a murine model of dextran sulfate sodium (DSS)-induced colitis. Next, we modulated the gut microbial community of mice by the EGCG pre-supplementation and then explored the resistant effects in colitis. Finally, we further demonstrated the alleviated effects of specific gut microbial community from EGCG-treated donor by comparing with the mice treated with FMT and sterile fecal filtrate (SFF) from control mice. MATERIALS AND METHODS Animals and induction of colitis Seven- to eight-week-old specific pathogen-free (SPF) female C57BL/6 J mice (SPF Biotechnology Co., Ltd., Beijing, China) were maintained with four animals per cage and housed in a standard SPF facility of China Agricultural University with a 12-h light and 12-h dark cycle at 22 °C. Colitis was induced by administration of DSS (molecular mass 36–40 kDa, MP Biologicals, Solon, OH, USA) through drinking water. Treatments and sample collection The experimental design has been shown in Fig. 1. After 1 week of acclimation, mice were randomly divided into six treatments with two cages of four mice per treatment. Animals were provided with free access to tap water supplemented with or without 2.5% DSS for 7 days, followed by daily oral or rectal administration of 100 μL PBS in the presence or absence of 50 mg/kg body weight of EGCG (purity ≥ 98%, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) for another 3 days. The treatment groups are as follows: (1) Oral-CON group: tap water for 7 days, followed by daily oral administration of PBS for 3 days; (2) DSS + Oral-PBS group: 2.5% DSS for 7 days, followed by daily oral administration of PBS for 3 days; (3) DSS + Oral-EGCG group: 2.5% DSS for 7 days, followed by daily oral administration of EGCG for 3 days; (1) Rectal-CON group: tap water for 7 days, followed by daily rectal administration of PBS for 3 days; (2) DSS + Rectal-PBS group: 2.5% DSS for 7 days, followed by daily rectal administration of PBS for 3 days; (3) DSS + Rectal-EGCG group: 2.5% DSS for 7 days, followed by daily rectal administration of EGCG for 3 days. [Figure: Study design for the whole experiment. EGCG, epigallocatechin-3-gallate; DSS, dextran sulfate sodium; FMT, fecal microbiota transplantation; SFF, sterile fecal filtrate] Body weight was measured daily for the entire duration of the study. Disease activity index (DAI) was evaluated to assess the severity of the colitis by combining scores of body weight loss, diarrhea of the stool, and the extent of blood in the feces [24, 25]. The mice were sacrificed after anesthesia on day 11, the length of the colon was measured, and fecal samples of all mice were collected sterilely and stored at − 80 °C for future analysis. Plasma was obtained by centrifugation (3000 × rpm for 15 min at 4 °C) and then stored at − 80 °C. A 5 mm segment of the mid-colon was flushed with PBS and then fixed in 10% formalin for subsequent histology analysis, while the remaining colon tissue was washed with PBS and snap frozen in liquid nitrogen for future analysis. To study the prophylactic efficacy of EGCG in alleviating colitis, another experiment was conducted using 7- to 8-week-old SPF female C57BL/6 J mice. After 1 week of acclimation, mice were randomly divided into four groups with eight mice per group and